Synapse - Neeta Pandit-Taskar

Results (43)

Feasibility of administering anti-CD45 iodine ((131)I) apamistamab [Iomab-B] for re-induction and targeted conditioning in older patients with active, relapsed or refractory AML without lead-lined rooms: SIERRA trial experience at MSKCC

Meeting Abstract

Chu, B. P.; Pandit-Taskar, N.; Gyurkocza, B.; Liang, Q.; Miodownik, D.; Reddy, V.; Berger, M. S.; Dauer, L. T.
Blood (2019)

Fulltext@MSK | Save

EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer

Journal Article

Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
Cancer Discovery (2019)

Fulltext@MSK | Save

A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with (89)Zr-Df-IAB2M in metastatic prostate cancer (PCa)

Meeting Abstract

Morris, M. J.; Martinez, D. F.; Durack, J. C.; Slovin, S. F.; Danila, D. C.; O'Donoghue, J. A.; Parada, N. A.; Lyashchenko, S. K.; Carrasquillo, J. A.; Ruan, S.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

PET-based compartmental modeling of (124)I-A33 antibody: Quantitative characterization of patient-specific tumor targeting in colorectal cancer

Journal Article

Zanzonico, P.; Carrasquillo, J. A.; Pandit-Taskar, N.; O'Donoghue, J. A.; Humm, J. L.; Smith-Jones, P.; Ruan, S.; Divgi, C.; Scott, A. M.; Kemeny, N. E.; more...
European Journal of Nuclear Medicine and Molecular Imaging (2015)

Fulltext@MSK | Save

Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591

Meeting Abstract

Feldman, J. L.; Morris, M. J.; Martinez, D. F.; Tagawa, S. T.; Nanus, D. M.; Solomon, S. B.; Carrasquillo, J. A.; Reuter, V. E.; Lewis, J. S.; O'Donoghue, J. A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591

Meeting Abstract

Feldman, J. L.; Morris, M. J.; Tagawa, S. T.; Nanus, D. M.; Solomon, S. B.; Carrasquillo, J. A.; Reuter, V. E.; Lewis, J. S.; O'Donoghue, J. A.; Martinez, D. F.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer

Journal Article

Autio, K. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Stephenson, R. D.; Slovin, S. F.; Rathkopf, D. E.; Hong, C.; Heller, G.; Scher, H. I.; Larson, S. M.; more...
Cancer (2013)

Fulltext@MSK | Save

Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

Journal Article

Carrasquillo, J. A.; O'Donoghue, J. A.; Pandit-Taskar, N.; Humm, J. L.; Rathkopf, D. E.; Slovin, S. F.; Williamson, M. J.; Lacuna, K.; Aksnes, A. K.; Larson, S. M.; more...
European Journal of Nuclear Medicine and Molecular Imaging (2013)

Fulltext@MSK | Save

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease

Journal Article

Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
Leukemia and Lymphoma (2012)

Fulltext@MSK | Save

Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)

Meeting Abstract

Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Ryan, C.; Frattini, M. G.; Cicic, D.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save